# A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

> **NCT02982954** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 211 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02982954
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2020-05-11
- **Final completion:** 2021-10-06
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2022-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982954, "A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02982954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*